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6/j.bThe impact of the rising prevalence of vancomycin-resistant Enterococcus (VRE) prior to hematopoietic stem
cell transplantation (HSCT) and changes in transplant techniques on risk of VREB (VRE bacteremia) early
after HSCT is not known. This is a retrospective study of 247 adult patients who underwent allogeneic
HSCT in the years 2008 and 2009 at the Memorial Sloan-Kettering Cancer Center. Sixty-eight of 247
(27.5%) patients were VRE colonized on pretransplant screening. VRE was the leading cause of bacteremia
in the first 30 days after HSCT; 23 of 43 (53.5%) patients with positive blood cultures had VRE. Only 13 (57%)
of the 23 patients with early VREB were colonized with VRE on pre-HSCT screening cultures. Mortality was
directly attributable to VRE infection in 9% of patients with early VREB. VRE is emerging as the most common
cause of preengraftment bacteremia in patients undergoing allogeneic HSCT, and is associated with substan-
tial mortality. Pre-HSCT screening for VRE with stool cultures will not identify all patients who are at risk for
VREB. The use of alternate agents with activity against Gram-positive bacteria for fever and neutropenia early
after HSCT should be evaluated further in prospective studies.
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Vancomycin-resistant Enterococcus (VRE) is a com-
mon problem among patients receiving hematopoietic
stem cell transplant (HSCT). Studies over the last 15
years, since the emergence of the pathogen, have
described rates of early VRE bacteremia (VREB) after
HSCT from 3.6% to 22%, with mortality ranging
from 0.04% to 85% [1-6].
In the years since the emergence of VRE, numer-
ous changes have occurred in the prevention and man-
agement of this infection; 4 new drugs with activity
against VRE are now available, and screening and
decolonizing strategies have been proposed. In addi-ctious Disease, Department of Medicine, Memorial
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tally changed, with the introduction of cord blood
grafts and nonmyeloablative conditioning regimens,
resulting in an ever-widening group of patients, in-
cluding those older than 60 years, who receive HSCT.
To better define the frequency and timing of VRE
infection after HSCT, we reviewed our recent experi-
ence with this organism among adult allogeneic
HSCT recipients. This information will facilitate the
development of an optimal approach for screening
and other preventive strategies for VRE.PATIENTS AND METHODS
The Memorial Sloan-Kettering Cancer Center
(MSKCC) institutional review board (IRB) reviewed
the study and granted a HIPPA waiver of authoriza-
tion. At the time of this study, the MSKCC was
a 432-bed tertiary care facility in New York City
with 19,000 annual admissions and 140,000 patient
days. The allogeneicHSCTdatabase was used to iden-
tify all adult patients admitted for an allogeneic HSCT
from January 1, 2008, to December 31, 2009. Elec-
tronic medical records, HSCT, and infection control
databases were used to retrieve demographic, clinical,
and laboratory information. The adult bone marrow
transplant (BMT) unit at MSKCC is comprised of
Biol Blood Marrow Transplant 16:1576-1581, 2010 1577Preengraftment bacteremia with VREa 29-bed unit. All allogeneicHSCTpatients are admit-
ted to private rooms and routinely placed under pro-
tective isolation (mask and gloves). All VRE
colonized and/or infected persons are placed under
barrier precautions. Since August 2004, all patients ad-
mitted for allogeneic transplant routinely undergo
screening for VRE colonization at admission and
weekly. Rectal swabs for VRE surveillance were col-
lected by patients for the most part of the study period
(January 2008 to June 2009) and by nurses for the last 6
months (July 2009 to December 2009). BBL Campy
CVA Agar is used to detect VRE from stool. If
Gram-positive cocci in pairs and chains are detected
on the Gram stain, further identification with catalase,
PYR, vancomycin disk susceptibility, and a Microscan
Positive ID 2 Panel is performed. Since June 2006, all
patients found to be VRE colonized on pre-HSCT
screening receive linezolid (instead of vancomycin) as
empiric therapy for fever and neutropenia (until blood
cultures are negative for 48 hours). Other antibacterial
prophylaxis includes intravenous (i.v.) vancomycin
(beginning day 22 for myeloablative (MA) regimens
and first fever for others), and fluoroquinolone from
day22 to engraftment or alternate antibiotic regimen.
Engraftment is defined by first day of 3 consecutive
days with an absolute neutrophil count (ANC) .500
cells/mL.
Statistical Analysis
Univariate analyses were performed by using chi-
square tests of independence for sex, primary disease,
transplant source, MA conditioning regimen, allograft
T cell depletion, and pretransplant VRE colonization.
Median age at time of transplant of infected and non-
infected patients was analyzed using the Wilcoxon
Mann-Whitney test. Variableswith a univariateP value
\.25 were incorporated into a multivariate model.
Transplant source was also included in the model.
A logit regression was used to predict VRE blood-
stream infection using primary disease, transplant
source, T cell depletion, VRE colonization, and age
at time of transplant. Primary disease was collapsed
into 3 categories: leukemia, lymphoma, and other
disorder category. All statistical analyses were per-
formed using SAS 9.1 (SAS, Cary, NC).RESULTS
During the study period (January 1, 2008, to
December 31, 2009), 307 patients underwent alloge-
neic HSCT, including 247 adults and 60 pediatric
patients (\18 years of age). No early VREB occurred
in a patient younger than 18 years and only 1 pediatric
HSCT recipient developed VREB after 30 days.
Among the adult patients, the median age was 50.8
years (range: 18.3-72.9 years) and 133 (61%) weremales. The demographic and transplant characteristics
of the adult HSCT population are shown in Table 1.
Sixty-eight of 247 (27.5%) patients were VRE
colonized on pretransplant screening. Twenty-seven
(11%) patients developed VREB in the posttransplant
period. In 23 of 27 (85%) patients, infection occurred
early, within the first 10 days after HSCT.
VREB Early after HSCT (First 30 Days)
VRE was the leading cause of first episode of bac-
teremia in the first 30 days after HSCT, accounting for
53.5% of all bacteremias followed by enteric Gram-
negative rods accounting for 30% of all bacteremias.
There were no secondary bacteremias because of
VRE. Among the 23 patients with VREB, VRE was
the first and only organism isolated from blood
cultures in the preengraftment period. Over 80% of
patients had VRE isolated from peripheral and central
venous catheter blood cultures, suggesting that the gut
may have been the source of VRE bacteremia. Only 2
patients had VRE isolated only from central venous
catheter blood culture.
All patients had prompt catheter removal. There
was no catheter exchange over the wire. Catheter tips
were not routinely cultured. Five catheter tips were
cultured and were positive for VRE.
Transplant Characteristics
All VREB in the early post-HSCTperiod occurred
within the first 3 to 10 days, with most infections
occurring around day 7 (39%) (Figure 1). The median
time to engraftment (ANC.500 cells/mL) was 11 days
(range: 1-37 days). Five of 40 (12.5%) cord blood
recipients and 17 of 194 (8.8%) PBSC recipients
developed VREB (P 5 .55).
Risk Factors Associated with VREB
In univariate analyses, age, primary disease, VRE
colonization, and T cell depletion were associated
with VRE bacteremia (Table 1). In multivariate analy-
ses, out of all predictors, onlypretransplant colonization
with VRE and T cell depletion were significant predic-
tors of VRE bloodstream infections, although the 95%
confidence intervals were notably very wide. Patients
colonizedwithVREhad3.88 timeshigher oddsof even-
tual bloodstream infection than patients who were not
colonized prior to transplant (VRE colonization 95%
confidence interval [CI] 1.50-10.04; p 5 .005 and
T cell depletion odds ratio [OR] 5 10.89, 95% CI
1.30-91.53; P5 .028).
Clinical Characteristics
Thirteen (57%) of the 23 patients with early VREB
were colonized with VRE on pre-HSCT screening
cultures. Six patients with negative initial screening
cultures were found to be colonized with VRE on
Table 1. Demographic andTransplant Characteristics of AdultHSCTRecipients Showing aComparison between Patients withNo
and Early VREB
No VRE Bloodstream Infection (%) Early VRE Bloodstream Infection (%) P-Value
Patients n 5 220* n 5 23
Median age (range) 50.8 (18.3-72.9) 58.2 (19.1-68.5)
Male 133 (60.55) 14 (60.9%)
Primary disease
Acute lymphoblastic leukemia 17 (7.7%) 5 (21.7%)
Acute myelogenous leukemia 79 (35.9%) 12 (52.2%)
Chronic lymphocytic leukemia 11 (5.0%) 0 (0%)
Chronic myelogenous leukemia 2 (0.9%) 0 (0%)
Hodgkin Lymphoma 10 (4.5%) 0 (0%)
Myelodysplastic syndrome 21 (9.5%) 3 (13.0%)
Multiple myeloma 11 (5.0%) 0 (0%)
Non-Hodgkin lymphoma 52 (23.6%) 1 (4.3%)
Others 17 (7.7%) 2 (8.7%)
Transplant characteristics
Myeloablative conditioning regimen 106 (48.2%) 11 (47.8%)
Allograft T cell depletion 101 (45.9%) 17 (73.9%) .01
Peripheral blood stem cell allograft 175 (79.5%) 17 (73.9%)
Bone marrow allograft 12 (5.5%) 1 (4.3%)
Cord blood allograft 33 (15.0%) 5 (21.7%)
HLA- matched sibling donor 74 (33.6%) 6 (26.1%)
Median follow-up for survivors (days) 336.5 (35-756) 357 (35-742)
Median days to ANC 500 engraftment (range) 11 (1-37) 11 (9-43)
VRE colonized pretransplant 55 (25.0%) 13 (56.5%) .001
VRE indicates vancomycin-resistant Enterococcus; ANC, absolute neutrophil count.
*Excludes 4 patients who developed VREB 90 days after HSCT.
1578 Biol Blood Marrow Transplant 16:1576-1581, 2010M. Kamboj et al.a subsequent culture, done after transplant but prior to
onset of bacteremia. The median duration of bacter-
emia was 2 days (range: 1-18 days). Mortality was
directly attributable to VRE infection in 2 of 23 pa-
tients with early VREB. The 30-day all cause mortality
for patients without early bacteremia was 2% com-
pared to 4.4% in patients with VRE bacteremia and
15% in patient with non-VRE bacteremia.
Four patients required ICU admission within 72
hours after the onset of VREB. One ICU admission
was because of narcotic overdose and the patient
quickly recovered. The remaining 3 patients devel-
oped a similar syndrome that included fever, dyspnea,
confusion, and mental status changes. All 3 had pro-
gressive declines in mental status, were intubated,
and required prolonged ICU care. No infection, other
than VREB, or other ascertainable cause of clinical
decline could be identified. Table 2 details the clinical
course of the 3 patients with this early VREB
syndrome. Patient #3 eventually recovered but
required tracheostomy. The other 2 patients died after
prolonged ICU stay; neither underwent autopsy.DISCUSSION
VRE emerged in the late 1980s and now is among
the most common causes of bacteremia in critically ill
and neutropenic patients with cancer [7]. Initially, an-
tibiotic choices for treatment of VRE infections were
limited and VREBwas associated with a highmortality
[2,5,8,9]. Since then, 4 antibiotics (quinupristin-
dalfopristin, linezolid, daptomycin, and tigecycline)with activity against VRE have been approved by the
FDA, and numerous prevention strategies have been
developed. In addition, conditioning regimens for
HSCT have changed. The impact of these basic
changes in the medical care of transplant patients on
VRE epidemiology and outcome has not been
described.
Previous studies from larger centers have reported
highly variable VRE colonization rates in HSCT re-
cipients ranging from 5% to 27%, although the rates
of VRE bacteremia among colonized patients was sim-
ilar: approximately 30% across all studies [5,10,11]. A
previous study from MSKCC (between August 2004
and February 2006) showed a colonization rate of
29%; 27 among 92 HSCT recipients screened prior
to transplant were VRE colonized, and 34% of all
colonized persons developed VREB early (within
first 35 days) after HSCT [4]. Because of the high oc-
currence of VREB among colonized persons in that
study atMSKCC, linezolid is used preemptively for fe-
ver early after HSCT in VRE colonized patients only
(Figure 2).
In a previous study from MSKCC by Almyroudis
et al. [1] (1999-2003), Streptococcus viridans and Entero-
bacteriacae followed by Enterococcus faecium were the
most common bacterial pathogens causing blood
stream infection (BSI) in the preengraftment period.
VREB occurred in 4.7% of all HSCT recipients in
the preengraftment period. Another study by Avery
et al. [2] at the Cleveland Clinic during the same
time period (1997-2003) described VREB incidence
of 3.6% among 281 allogeneic HSCT recipients in
the preengraftment period.
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Biol Blood Marrow Transplant 16:1576-1581, 2010 1579Preengraftment bacteremia with VRESince the MSKCC study by Almyroudis et al. [1],
we have used vancomycin prophylaxis (beginning late
2005) in the peritransplant period for prevention of
S. viridans in myeloablative HSCTs [12] and fluoro-
quinolone prophylaxis (since 2006) is routinely used
in HSCT recipients (Figure 2) [13]. Our current study
has several important findings; we have reported a high
pre-HSCT prevalence of VRE colonization in a much
larger cohort of patients undergoing HSCT at
MSKCC than previously described [4]. In addition,
we have observed a shift in the spectrum of bacteria
causing BSIs in the preengraftment period. VRE
now accounts for the majority of the infections
(53.5%), and the rate of VREB early after HSCT has
almost doubled (from 5% in previous study to 9.3%
in the current study); Streptococcus viridans BSI rates
in the preengraftment period have declined from
8.1% (1999-2003) to 1.3% (current study).We believe
the cause of change in epidemiology of preengraftment
BSI’s is multifactorial; first, antibacterials that disrupt
commensal Gram-negative bacteria (such as ciproflox-
acin) promote high-grade VRE colonization by
disrupting innate immune defense mechanisms in the
gut [14], and vancomycin use, which has been previ-
ously identified as a risk factor for VRE [15], has
increased significantly in our transplant population.
We believe the increased use of these 2 drugs for pro-
phylaxis in HSCT recipients has played a role in the
emergence of VRE as a predominant pathogen early
after HSCT. Second, the prevalence of gastrointesti-
nal colonization of VRE has probably increased since
the previous report by Almyroudis et al. [1].
In the current series, all cases of early VREB
occurred within the first 10 days after transplant, and
mostly periengraftment. Although severe cases of
VREBearly afterHSCThave been reported previously
[9], the risk period for infection is not well defined.The
current study and previous reports from our institution
[1,4] identify the highest risk for VREB during the first
2 weeks after HSCT, particularly periengraftment,
which may in part relate to the period when the
presence of mucositis is greatest and barriers against
VRE in the gastrointestinal tract are the lowest.
Currently, the ASBMT guidelines do not make
recommendations regarding routine screening and
prophylaxis for VRE [16]. However, the high preva-
lence of VRE among leukemia and HSCT patients
has been commonly described [3,6,8,9,17-20]. In the
current study, pre-HSCT screening alone identified
13 of 23 (56.5%) patients who subsequently developed
VREB, and an additional 6 patients were found to be
colonized on a follow-up culture after initial negative
screen. Five percent of noncolonized (on pre-HSCT
screen) developed VREB, much lower than the inci-
dence (13 of 555 24%) in VRE carriers, but concern-
ing nevertheless. Pre-HSCT screening and weekly
surveillance identified approximately 80% of patients
Figure 1. Frequency of VREB by days posttransplant (until day 130).
1580 Biol Blood Marrow Transplant 16:1576-1581, 2010M. Kamboj et al.at risk. Although nosocomial acquisition of VRE is
certainly a possibility in the 4 patients who developed
VREBwith negative stool screening for VRE, variabil-
ity in sample collection technique and poor sensitivity
of culture-based methods for detection of VRE is well
recognized [21]. Our findings suggest that pre-HSCT
screening alone will miss a proportion of patients at
risk for VREB, and prophylactic strategies should
not be guided entirely by pre HSCT stool screening
results. Few studies have evaluated the utility of poly-
merase chain reaction (PCR)-based approaches for
detection of VRE in this setting [5].
Therapy with an agent active against VRE in all
patients with fever (regardless of VRE colonization)
in the most vulnerable period after HSCT merits
clinical investigation. The current choices include
linezolid, quinupristin-dalfopristin, daptomycin, and
tigecycline. Of these, only linezolid and quinupristin-Figure 2. Incidence and attributable mortality from VREB in the preengraftm
and changes in prophylactic antibacterial regimens during the study years.dalfopristin are FDA approved for treatment of
VRE. Linezolid, in particular, appears to be safe
when used in HSCT patients [22]; resistance among
VRE to linezolid occurs rarely, and has been reported
after prolonged use [23-25]. However, the effect of
early use of linezolid in HSCTs on VREB and
mortality from VRE infections should be evaluated
further in prospective studies. Last, we have reported
3 cases of severe VREB early after HSCT. Although
we cannot attribute all the clinical findings to VRE
infection because of a lack of autopsy information,
the similarity in clinical presentation among all 3
patients is striking, and demonstrates that acute
decompensation can occur with this bacteria. This
supports an aggressive approach in devising
preventive strategies for VRE in HSCT recipients.
This study has several limitations: (1) its retrospec-
tive design, (2) BSI rates per transplant days for early
VREB were not determined, (3) the impact of preemp-
tive linezolid use in prevention of VRE infection and
mortality was not assessed, (4) the technique for collec-
tion of rectal swabs changed during the study period:
samples for VRE surveillance were collected by pa-
tients before June 2009 and by nurses in the last 6
months of the study period. Last, the antibiotic regi-
men for empiric treatment of fever and neutropenia
needs to be tailored for individual transplant centers
in the context of their patient population and hospital
epidemiology.ent period from 3 studies done at MSKCC, with VRE colonization rates
Biol Blood Marrow Transplant 16:1576-1581, 2010 1581Preengraftment bacteremia with VREIn conclusion, we have reported a change in the
spectrum of bacteria causing BSIs early after HSCT,
with emergence of VRE as a dominant pathogen in
the preengraftment period. VRE colonization is pre-
dictive of infection, but more sensitive and accurate
screening methods are needed. The empiric use of
Gram-positive agents with activity against VRE in all
patients with fever in the preengraftment period needs
formal investigation. Studies in the prevention of VRE
colonization and bacteremia during HSCT need to
target infectious disease management of patients
during treatment of their primary malignancy.ACKNOWLEDGMENTS
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